Global Vaccine Adjuvants Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030
Summary
An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.
According to APO Research, The global Vaccine Adjuvants market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for Vaccine Adjuvants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Vaccine Adjuvants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Vaccine Adjuvants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Vaccine Adjuvants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Vaccine Adjuvants include GSK, CSL Limited, Croda, SEPPIC, Novavax, SPI Pharma, Phibro, SDA BIO and Invivogen, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Vaccine Adjuvants, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Vaccine Adjuvants, also provides the sales of main regions and countries. Of the upcoming market potential for Vaccine Adjuvants, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Vaccine Adjuvants sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Vaccine Adjuvants market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Vaccine Adjuvants sales, projected growth trends, production technology, application and end-user industry.
Vaccine Adjuvants segment by Company
1. To analyze and research the global Vaccine Adjuvants status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Vaccine Adjuvants market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Vaccine Adjuvants significant trends, drivers, influence factors in global and regions.
6. To analyze Vaccine Adjuvants competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine Adjuvants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vaccine Adjuvants and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine Adjuvants.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Vaccine Adjuvants market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2019-2030).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vaccine Adjuvants industry.
Chapter 3: Detailed analysis of Vaccine Adjuvants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Vaccine Adjuvants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Vaccine Adjuvants in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.
According to APO Research, The global Vaccine Adjuvants market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for Vaccine Adjuvants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Vaccine Adjuvants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Vaccine Adjuvants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Vaccine Adjuvants is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Vaccine Adjuvants include GSK, CSL Limited, Croda, SEPPIC, Novavax, SPI Pharma, Phibro, SDA BIO and Invivogen, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Vaccine Adjuvants, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Vaccine Adjuvants, also provides the sales of main regions and countries. Of the upcoming market potential for Vaccine Adjuvants, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Vaccine Adjuvants sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Vaccine Adjuvants market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Vaccine Adjuvants sales, projected growth trends, production technology, application and end-user industry.
Vaccine Adjuvants segment by Company
- GSK
- CSL Limited
- Croda
- SEPPIC
- Novavax
- SPI Pharma
- Phibro
- SDA BIO
- Invivogen
- Tj Kaiwei
- OZ Biosciences
- Brenntag Biosector
- MVP Laboratories
- Zhuoyue
- Aphios
- Aluminum Adjuvant
- Emulsions Adjuvant
- Others
- Human Vaccine
- Veterinary Vaccine
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global Vaccine Adjuvants status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Vaccine Adjuvants market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Vaccine Adjuvants significant trends, drivers, influence factors in global and regions.
6. To analyze Vaccine Adjuvants competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine Adjuvants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vaccine Adjuvants and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine Adjuvants.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Vaccine Adjuvants market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2019-2030).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vaccine Adjuvants industry.
Chapter 3: Detailed analysis of Vaccine Adjuvants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Vaccine Adjuvants in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Vaccine Adjuvants in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Vaccine Adjuvants Sales Value (2019-2030)
1.2.2 Global Vaccine Adjuvants Sales Volume (2019-2030)
1.2.3 Global Vaccine Adjuvants Sales Average Price (2019-2030)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 VACCINE ADJUVANTS MARKET DYNAMICS
2.1 Vaccine Adjuvants Industry Trends
2.2 Vaccine Adjuvants Industry Drivers
2.3 Vaccine Adjuvants Industry Opportunities and Challenges
2.4 Vaccine Adjuvants Industry Restraints
3 VACCINE ADJUVANTS MARKET BY COMPANY
3.1 Global Vaccine Adjuvants Company Revenue Ranking in 2023
3.2 Global Vaccine Adjuvants Revenue by Company (2019-2024)
3.3 Global Vaccine Adjuvants Sales Volume by Company (2019-2024)
3.4 Global Vaccine Adjuvants Average Price by Company (2019-2024)
3.5 Global Vaccine Adjuvants Company Ranking, 2022 VS 2023 VS 2024
3.6 Global Vaccine Adjuvants Company Manufacturing Base & Headquarters
3.7 Global Vaccine Adjuvants Company, Product Type & Application
3.8 Global Vaccine Adjuvants Company Commercialization Time
3.9 Market Competitive Analysis
3.9.1 Global Vaccine Adjuvants Market CR5 and HHI
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.9.3 2023 Vaccine Adjuvants Tier 1, Tier 2, and Tier
3.10 Mergers & Acquisitions, Expansion
4 VACCINE ADJUVANTS MARKET BY TYPE
4.1 Vaccine Adjuvants Type Introduction
4.1.1 Aluminum Adjuvant
4.1.2 Emulsions Adjuvant
4.1.3 Others
4.2 Global Vaccine Adjuvants Sales Volume by Type
4.2.1 Global Vaccine Adjuvants Sales Volume by Type (2019 VS 2023 VS 2030)
4.2.2 Global Vaccine Adjuvants Sales Volume by Type (2019-2030)
4.2.3 Global Vaccine Adjuvants Sales Volume Share by Type (2019-2030)
4.3 Global Vaccine Adjuvants Sales Value by Type
4.3.1 Global Vaccine Adjuvants Sales Value by Type (2019 VS 2023 VS 2030)
4.3.2 Global Vaccine Adjuvants Sales Value by Type (2019-2030)
4.3.3 Global Vaccine Adjuvants Sales Value Share by Type (2019-2030)
5 VACCINE ADJUVANTS MARKET BY APPLICATION
5.1 Vaccine Adjuvants Application Introduction
5.1.1 Human Vaccine
5.1.2 Veterinary Vaccine
5.2 Global Vaccine Adjuvants Sales Volume by Application
5.2.1 Global Vaccine Adjuvants Sales Volume by Application (2019 VS 2023 VS 2030)
5.2.2 Global Vaccine Adjuvants Sales Volume by Application (2019-2030)
5.2.3 Global Vaccine Adjuvants Sales Volume Share by Application (2019-2030)
5.3 Global Vaccine Adjuvants Sales Value by Application
5.3.1 Global Vaccine Adjuvants Sales Value by Application (2019 VS 2023 VS 2030)
5.3.2 Global Vaccine Adjuvants Sales Value by Application (2019-2030)
5.3.3 Global Vaccine Adjuvants Sales Value Share by Application (2019-2030)
6 VACCINE ADJUVANTS MARKET BY REGION
6.1 Global Vaccine Adjuvants Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Vaccine Adjuvants Sales by Region (2019-2030)
6.2.1 Global Vaccine Adjuvants Sales by Region: 2019-2024
6.2.2 Global Vaccine Adjuvants Sales by Region (2025-2030)
6.3 Global Vaccine Adjuvants Sales Value by Region: 2019 VS 2023 VS 2030
6.4 Global Vaccine Adjuvants Sales Value by Region (2019-2030)
6.4.1 Global Vaccine Adjuvants Sales Value by Region: 2019-2024
6.4.2 Global Vaccine Adjuvants Sales Value by Region (2025-2030)
6.5 Global Vaccine Adjuvants Market Price Analysis by Region (2019-2024)
6.6 North America
6.6.1 North America Vaccine Adjuvants Sales Value (2019-2030)
6.6.2 North America Vaccine Adjuvants Sales Value Share by Country, 2023 VS 2030
6.7 Europe
6.7.1 Europe Vaccine Adjuvants Sales Value (2019-2030)
6.7.2 Europe Vaccine Adjuvants Sales Value Share by Country, 2023 VS 2030
6.8 Asia-Pacific
6.8.1 Asia-Pacific Vaccine Adjuvants Sales Value (2019-2030)
6.8.2 Asia-Pacific Vaccine Adjuvants Sales Value Share by Country, 2023 VS 2030
6.9 Latin America
6.9.1 Latin America Vaccine Adjuvants Sales Value (2019-2030)
6.9.2 Latin America Vaccine Adjuvants Sales Value Share by Country, 2023 VS 2030
6.10 Middle East & Africa
6.10.1 Middle East & Africa Vaccine Adjuvants Sales Value (2019-2030)
6.10.2 Middle East & Africa Vaccine Adjuvants Sales Value Share by Country, 2023 VS 2030
7 VACCINE ADJUVANTS MARKET BY COUNTRY
7.1 Global Vaccine Adjuvants Sales by Country: 2019 VS 2023 VS 2030
7.2 Global Vaccine Adjuvants Sales Value by Country: 2019 VS 2023 VS 2030
7.3 Global Vaccine Adjuvants Sales by Country (2019-2030)
7.3.1 Global Vaccine Adjuvants Sales by Country (2019-2024)
7.3.2 Global Vaccine Adjuvants Sales by Country (2025-2030)
7.4 Global Vaccine Adjuvants Sales Value by Country (2019-2030)
7.4.1 Global Vaccine Adjuvants Sales Value by Country (2019-2024)
7.4.2 Global Vaccine Adjuvants Sales Value by Country (2025-2030)
7.5 USA
7.5.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.5.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.6 Canada
7.6.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.6.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.7 Germany
7.7.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.7.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.8 France
7.8.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.8.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.9 U.K.
7.9.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.9.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.10 Italy
7.10.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.10.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.11 Netherlands
7.11.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.11.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.12 Nordic Countries
7.12.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.12.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.13 China
7.13.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.13.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.14 Japan
7.14.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.14.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.15 South Korea
7.15.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.15.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.16 Southeast Asia
7.16.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.16.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.17 India
7.17.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.17.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.18 Australia
7.18.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.18.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.19 Mexico
7.19.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.19.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.20 Brazil
7.20.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.20.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.21 Turkey
7.21.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.21.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.22 Saudi Arabia
7.22.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.22.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.22.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.23 UAE
7.23.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.23.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.23.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 GSK
8.1.1 GSK Comapny Information
8.1.2 GSK Business Overview
8.1.3 GSK Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.1.4 GSK Vaccine Adjuvants Product Portfolio
8.1.5 GSK Recent Developments
8.2 CSL Limited
8.2.1 CSL Limited Comapny Information
8.2.2 CSL Limited Business Overview
8.2.3 CSL Limited Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.2.4 CSL Limited Vaccine Adjuvants Product Portfolio
8.2.5 CSL Limited Recent Developments
8.3 Croda
8.3.1 Croda Comapny Information
8.3.2 Croda Business Overview
8.3.3 Croda Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.3.4 Croda Vaccine Adjuvants Product Portfolio
8.3.5 Croda Recent Developments
8.4 SEPPIC
8.4.1 SEPPIC Comapny Information
8.4.2 SEPPIC Business Overview
8.4.3 SEPPIC Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.4.4 SEPPIC Vaccine Adjuvants Product Portfolio
8.4.5 SEPPIC Recent Developments
8.5 Novavax
8.5.1 Novavax Comapny Information
8.5.2 Novavax Business Overview
8.5.3 Novavax Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.5.4 Novavax Vaccine Adjuvants Product Portfolio
8.5.5 Novavax Recent Developments
8.6 SPI Pharma
8.6.1 SPI Pharma Comapny Information
8.6.2 SPI Pharma Business Overview
8.6.3 SPI Pharma Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.6.4 SPI Pharma Vaccine Adjuvants Product Portfolio
8.6.5 SPI Pharma Recent Developments
8.7 Phibro
8.7.1 Phibro Comapny Information
8.7.2 Phibro Business Overview
8.7.3 Phibro Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.7.4 Phibro Vaccine Adjuvants Product Portfolio
8.7.5 Phibro Recent Developments
8.8 SDA BIO
8.8.1 SDA BIO Comapny Information
8.8.2 SDA BIO Business Overview
8.8.3 SDA BIO Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.8.4 SDA BIO Vaccine Adjuvants Product Portfolio
8.8.5 SDA BIO Recent Developments
8.9 Invivogen
8.9.1 Invivogen Comapny Information
8.9.2 Invivogen Business Overview
8.9.3 Invivogen Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.9.4 Invivogen Vaccine Adjuvants Product Portfolio
8.9.5 Invivogen Recent Developments
8.10 Tj Kaiwei
8.10.1 Tj Kaiwei Comapny Information
8.10.2 Tj Kaiwei Business Overview
8.10.3 Tj Kaiwei Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.10.4 Tj Kaiwei Vaccine Adjuvants Product Portfolio
8.10.5 Tj Kaiwei Recent Developments
8.11 OZ Biosciences
8.11.1 OZ Biosciences Comapny Information
8.11.2 OZ Biosciences Business Overview
8.11.3 OZ Biosciences Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.11.4 OZ Biosciences Vaccine Adjuvants Product Portfolio
8.11.5 OZ Biosciences Recent Developments
8.12 Brenntag Biosector
8.12.1 Brenntag Biosector Comapny Information
8.12.2 Brenntag Biosector Business Overview
8.12.3 Brenntag Biosector Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.12.4 Brenntag Biosector Vaccine Adjuvants Product Portfolio
8.12.5 Brenntag Biosector Recent Developments
8.13 MVP Laboratories
8.13.1 MVP Laboratories Comapny Information
8.13.2 MVP Laboratories Business Overview
8.13.3 MVP Laboratories Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.13.4 MVP Laboratories Vaccine Adjuvants Product Portfolio
8.13.5 MVP Laboratories Recent Developments
8.14 Zhuoyue
8.14.1 Zhuoyue Comapny Information
8.14.2 Zhuoyue Business Overview
8.14.3 Zhuoyue Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.14.4 Zhuoyue Vaccine Adjuvants Product Portfolio
8.14.5 Zhuoyue Recent Developments
8.15 Aphios
8.15.1 Aphios Comapny Information
8.15.2 Aphios Business Overview
8.15.3 Aphios Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.15.4 Aphios Vaccine Adjuvants Product Portfolio
8.15.5 Aphios Recent Developments
9 VALUE CHAIN AND SALES CHANNELS ANALYSIS
9.1 Vaccine Adjuvants Value Chain Analysis
9.1.1 Vaccine Adjuvants Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Vaccine Adjuvants Sales Mode & Process
9.2 Vaccine Adjuvants Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Vaccine Adjuvants Distributors
9.2.3 Vaccine Adjuvants Customers
10 CONCLUDING INSIGHTS
11 APPENDIX
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Vaccine Adjuvants Sales Value (2019-2030)
1.2.2 Global Vaccine Adjuvants Sales Volume (2019-2030)
1.2.3 Global Vaccine Adjuvants Sales Average Price (2019-2030)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 VACCINE ADJUVANTS MARKET DYNAMICS
2.1 Vaccine Adjuvants Industry Trends
2.2 Vaccine Adjuvants Industry Drivers
2.3 Vaccine Adjuvants Industry Opportunities and Challenges
2.4 Vaccine Adjuvants Industry Restraints
3 VACCINE ADJUVANTS MARKET BY COMPANY
3.1 Global Vaccine Adjuvants Company Revenue Ranking in 2023
3.2 Global Vaccine Adjuvants Revenue by Company (2019-2024)
3.3 Global Vaccine Adjuvants Sales Volume by Company (2019-2024)
3.4 Global Vaccine Adjuvants Average Price by Company (2019-2024)
3.5 Global Vaccine Adjuvants Company Ranking, 2022 VS 2023 VS 2024
3.6 Global Vaccine Adjuvants Company Manufacturing Base & Headquarters
3.7 Global Vaccine Adjuvants Company, Product Type & Application
3.8 Global Vaccine Adjuvants Company Commercialization Time
3.9 Market Competitive Analysis
3.9.1 Global Vaccine Adjuvants Market CR5 and HHI
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.9.3 2023 Vaccine Adjuvants Tier 1, Tier 2, and Tier
3.10 Mergers & Acquisitions, Expansion
4 VACCINE ADJUVANTS MARKET BY TYPE
4.1 Vaccine Adjuvants Type Introduction
4.1.1 Aluminum Adjuvant
4.1.2 Emulsions Adjuvant
4.1.3 Others
4.2 Global Vaccine Adjuvants Sales Volume by Type
4.2.1 Global Vaccine Adjuvants Sales Volume by Type (2019 VS 2023 VS 2030)
4.2.2 Global Vaccine Adjuvants Sales Volume by Type (2019-2030)
4.2.3 Global Vaccine Adjuvants Sales Volume Share by Type (2019-2030)
4.3 Global Vaccine Adjuvants Sales Value by Type
4.3.1 Global Vaccine Adjuvants Sales Value by Type (2019 VS 2023 VS 2030)
4.3.2 Global Vaccine Adjuvants Sales Value by Type (2019-2030)
4.3.3 Global Vaccine Adjuvants Sales Value Share by Type (2019-2030)
5 VACCINE ADJUVANTS MARKET BY APPLICATION
5.1 Vaccine Adjuvants Application Introduction
5.1.1 Human Vaccine
5.1.2 Veterinary Vaccine
5.2 Global Vaccine Adjuvants Sales Volume by Application
5.2.1 Global Vaccine Adjuvants Sales Volume by Application (2019 VS 2023 VS 2030)
5.2.2 Global Vaccine Adjuvants Sales Volume by Application (2019-2030)
5.2.3 Global Vaccine Adjuvants Sales Volume Share by Application (2019-2030)
5.3 Global Vaccine Adjuvants Sales Value by Application
5.3.1 Global Vaccine Adjuvants Sales Value by Application (2019 VS 2023 VS 2030)
5.3.2 Global Vaccine Adjuvants Sales Value by Application (2019-2030)
5.3.3 Global Vaccine Adjuvants Sales Value Share by Application (2019-2030)
6 VACCINE ADJUVANTS MARKET BY REGION
6.1 Global Vaccine Adjuvants Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Vaccine Adjuvants Sales by Region (2019-2030)
6.2.1 Global Vaccine Adjuvants Sales by Region: 2019-2024
6.2.2 Global Vaccine Adjuvants Sales by Region (2025-2030)
6.3 Global Vaccine Adjuvants Sales Value by Region: 2019 VS 2023 VS 2030
6.4 Global Vaccine Adjuvants Sales Value by Region (2019-2030)
6.4.1 Global Vaccine Adjuvants Sales Value by Region: 2019-2024
6.4.2 Global Vaccine Adjuvants Sales Value by Region (2025-2030)
6.5 Global Vaccine Adjuvants Market Price Analysis by Region (2019-2024)
6.6 North America
6.6.1 North America Vaccine Adjuvants Sales Value (2019-2030)
6.6.2 North America Vaccine Adjuvants Sales Value Share by Country, 2023 VS 2030
6.7 Europe
6.7.1 Europe Vaccine Adjuvants Sales Value (2019-2030)
6.7.2 Europe Vaccine Adjuvants Sales Value Share by Country, 2023 VS 2030
6.8 Asia-Pacific
6.8.1 Asia-Pacific Vaccine Adjuvants Sales Value (2019-2030)
6.8.2 Asia-Pacific Vaccine Adjuvants Sales Value Share by Country, 2023 VS 2030
6.9 Latin America
6.9.1 Latin America Vaccine Adjuvants Sales Value (2019-2030)
6.9.2 Latin America Vaccine Adjuvants Sales Value Share by Country, 2023 VS 2030
6.10 Middle East & Africa
6.10.1 Middle East & Africa Vaccine Adjuvants Sales Value (2019-2030)
6.10.2 Middle East & Africa Vaccine Adjuvants Sales Value Share by Country, 2023 VS 2030
7 VACCINE ADJUVANTS MARKET BY COUNTRY
7.1 Global Vaccine Adjuvants Sales by Country: 2019 VS 2023 VS 2030
7.2 Global Vaccine Adjuvants Sales Value by Country: 2019 VS 2023 VS 2030
7.3 Global Vaccine Adjuvants Sales by Country (2019-2030)
7.3.1 Global Vaccine Adjuvants Sales by Country (2019-2024)
7.3.2 Global Vaccine Adjuvants Sales by Country (2025-2030)
7.4 Global Vaccine Adjuvants Sales Value by Country (2019-2030)
7.4.1 Global Vaccine Adjuvants Sales Value by Country (2019-2024)
7.4.2 Global Vaccine Adjuvants Sales Value by Country (2025-2030)
7.5 USA
7.5.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.5.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.6 Canada
7.6.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.6.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.7 Germany
7.7.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.7.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.8 France
7.8.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.8.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.9 U.K.
7.9.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.9.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.10 Italy
7.10.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.10.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.11 Netherlands
7.11.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.11.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.12 Nordic Countries
7.12.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.12.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.13 China
7.13.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.13.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.14 Japan
7.14.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.14.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.15 South Korea
7.15.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.15.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.16 Southeast Asia
7.16.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.16.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.17 India
7.17.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.17.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.18 Australia
7.18.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.18.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.19 Mexico
7.19.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.19.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.20 Brazil
7.20.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.20.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.21 Turkey
7.21.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.21.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.22 Saudi Arabia
7.22.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.22.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.22.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
7.23 UAE
7.23.1 Global Vaccine Adjuvants Sales Value Growth Rate (2019-2030)
7.23.2 Global Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030
7.23.3 Global Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 GSK
8.1.1 GSK Comapny Information
8.1.2 GSK Business Overview
8.1.3 GSK Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.1.4 GSK Vaccine Adjuvants Product Portfolio
8.1.5 GSK Recent Developments
8.2 CSL Limited
8.2.1 CSL Limited Comapny Information
8.2.2 CSL Limited Business Overview
8.2.3 CSL Limited Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.2.4 CSL Limited Vaccine Adjuvants Product Portfolio
8.2.5 CSL Limited Recent Developments
8.3 Croda
8.3.1 Croda Comapny Information
8.3.2 Croda Business Overview
8.3.3 Croda Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.3.4 Croda Vaccine Adjuvants Product Portfolio
8.3.5 Croda Recent Developments
8.4 SEPPIC
8.4.1 SEPPIC Comapny Information
8.4.2 SEPPIC Business Overview
8.4.3 SEPPIC Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.4.4 SEPPIC Vaccine Adjuvants Product Portfolio
8.4.5 SEPPIC Recent Developments
8.5 Novavax
8.5.1 Novavax Comapny Information
8.5.2 Novavax Business Overview
8.5.3 Novavax Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.5.4 Novavax Vaccine Adjuvants Product Portfolio
8.5.5 Novavax Recent Developments
8.6 SPI Pharma
8.6.1 SPI Pharma Comapny Information
8.6.2 SPI Pharma Business Overview
8.6.3 SPI Pharma Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.6.4 SPI Pharma Vaccine Adjuvants Product Portfolio
8.6.5 SPI Pharma Recent Developments
8.7 Phibro
8.7.1 Phibro Comapny Information
8.7.2 Phibro Business Overview
8.7.3 Phibro Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.7.4 Phibro Vaccine Adjuvants Product Portfolio
8.7.5 Phibro Recent Developments
8.8 SDA BIO
8.8.1 SDA BIO Comapny Information
8.8.2 SDA BIO Business Overview
8.8.3 SDA BIO Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.8.4 SDA BIO Vaccine Adjuvants Product Portfolio
8.8.5 SDA BIO Recent Developments
8.9 Invivogen
8.9.1 Invivogen Comapny Information
8.9.2 Invivogen Business Overview
8.9.3 Invivogen Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.9.4 Invivogen Vaccine Adjuvants Product Portfolio
8.9.5 Invivogen Recent Developments
8.10 Tj Kaiwei
8.10.1 Tj Kaiwei Comapny Information
8.10.2 Tj Kaiwei Business Overview
8.10.3 Tj Kaiwei Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.10.4 Tj Kaiwei Vaccine Adjuvants Product Portfolio
8.10.5 Tj Kaiwei Recent Developments
8.11 OZ Biosciences
8.11.1 OZ Biosciences Comapny Information
8.11.2 OZ Biosciences Business Overview
8.11.3 OZ Biosciences Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.11.4 OZ Biosciences Vaccine Adjuvants Product Portfolio
8.11.5 OZ Biosciences Recent Developments
8.12 Brenntag Biosector
8.12.1 Brenntag Biosector Comapny Information
8.12.2 Brenntag Biosector Business Overview
8.12.3 Brenntag Biosector Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.12.4 Brenntag Biosector Vaccine Adjuvants Product Portfolio
8.12.5 Brenntag Biosector Recent Developments
8.13 MVP Laboratories
8.13.1 MVP Laboratories Comapny Information
8.13.2 MVP Laboratories Business Overview
8.13.3 MVP Laboratories Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.13.4 MVP Laboratories Vaccine Adjuvants Product Portfolio
8.13.5 MVP Laboratories Recent Developments
8.14 Zhuoyue
8.14.1 Zhuoyue Comapny Information
8.14.2 Zhuoyue Business Overview
8.14.3 Zhuoyue Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.14.4 Zhuoyue Vaccine Adjuvants Product Portfolio
8.14.5 Zhuoyue Recent Developments
8.15 Aphios
8.15.1 Aphios Comapny Information
8.15.2 Aphios Business Overview
8.15.3 Aphios Vaccine Adjuvants Sales, Value and Gross Margin (2019-2024)
8.15.4 Aphios Vaccine Adjuvants Product Portfolio
8.15.5 Aphios Recent Developments
9 VALUE CHAIN AND SALES CHANNELS ANALYSIS
9.1 Vaccine Adjuvants Value Chain Analysis
9.1.1 Vaccine Adjuvants Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Vaccine Adjuvants Sales Mode & Process
9.2 Vaccine Adjuvants Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Vaccine Adjuvants Distributors
9.2.3 Vaccine Adjuvants Customers
10 CONCLUDING INSIGHTS
11 APPENDIX
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
LIST OF TABLES
Table 1. Vaccine Adjuvants Industry Trends
Table 2. Vaccine Adjuvants Industry Drivers
Table 3. Vaccine Adjuvants Industry Opportunities and Challenges
Table 4. Vaccine Adjuvants Industry Restraints
Table 5. Global Vaccine Adjuvants Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global Vaccine Adjuvants Revenue Share by Company (2019-2024)
Table 7. Global Vaccine Adjuvants Sales Volume by Company (MT) & (2019-2024)
Table 8. Global Vaccine Adjuvants Sales Volume Share by Company (2019-2024)
Table 9. Global Vaccine Adjuvants Average Price (USD/Kg) of Company (2019-2024)
Table 10. Global Vaccine Adjuvants Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 11. Global Vaccine Adjuvants Key Company Manufacturing Base & Headquarters
Table 12. Global Vaccine Adjuvants Company, Product Type & Application
Table 13. Global Vaccine Adjuvants Company Commercialization Time
Table 14. Global Company Market Concentration Ratio (CR5 and HHI)
Table 15. Global Vaccine Adjuvants by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 16. Mergers & Acquisitions, Expansion
Table 17. Major Companies of Aluminum Adjuvant
Table 18. Major Companies of Emulsions Adjuvant
Table 19. Major Companies of Others
Table 20. Global Vaccine Adjuvants Sales Volume by Type 2019 VS 2023 VS 2030 (MT)
Table 21. Global Vaccine Adjuvants Sales Volume by Type (2019-2024) & (MT)
Table 22. Global Vaccine Adjuvants Sales Volume by Type (2025-2030) & (MT)
Table 23. Global Vaccine Adjuvants Sales Volume Share by Type (2019-2024)
Table 24. Global Vaccine Adjuvants Sales Volume Share by Type (2025-2030)
Table 25. Global Vaccine Adjuvants Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 26. Global Vaccine Adjuvants Sales Value by Type (2019-2024) & (US$ Million)
Table 27. Global Vaccine Adjuvants Sales Value by Type (2025-2030) & (US$ Million)
Table 28. Global Vaccine Adjuvants Sales Value Share by Type (2019-2024)
Table 29. Global Vaccine Adjuvants Sales Value Share by Type (2025-2030)
Table 30. Major Companies of Human Vaccine
Table 31. Major Companies of Veterinary Vaccine
Table 32. Global Vaccine Adjuvants Sales Volume by Application 2019 VS 2023 VS 2030 (MT)
Table 33. Global Vaccine Adjuvants Sales Volume by Application (2019-2024) & (MT)
Table 34. Global Vaccine Adjuvants Sales Volume by Application (2025-2030) & (MT)
Table 35. Global Vaccine Adjuvants Sales Volume Share by Application (2019-2024)
Table 36. Global Vaccine Adjuvants Sales Volume Share by Application (2025-2030)
Table 37. Global Vaccine Adjuvants Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 38. Global Vaccine Adjuvants Sales Value by Application (2019-2024) & (US$ Million)
Table 39. Global Vaccine Adjuvants Sales Value by Application (2025-2030) & (US$ Million)
Table 40. Global Vaccine Adjuvants Sales Value Share by Application (2019-2024)
Table 41. Global Vaccine Adjuvants Sales Value Share by Application (2025-2030)
Table 42. Global Vaccine Adjuvants Sales by Region: 2019 VS 2023 VS 2030 (MT)
Table 43. Global Vaccine Adjuvants Sales by Region (2019-2024) & (MT)
Table 44. Global Vaccine Adjuvants Sales Market Share by Region (2019-2024)
Table 45. Global Vaccine Adjuvants Sales by Region (2025-2030) & (MT)
Table 46. Global Vaccine Adjuvants Sales Market Share by Region (2025-2030)
Table 47. Global Vaccine Adjuvants Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 48. Global Vaccine Adjuvants Sales Value by Region (2019-2024) & (US$ Million)
Table 49. Global Vaccine Adjuvants Sales Value Share by Region (2019-2024)
Table 50. Global Vaccine Adjuvants Sales Value by Region (2025-2030) & (US$ Million)
Table 51. Global Vaccine Adjuvants Sales Value Share by Region (2025-2030)
Table 52. Global Vaccine Adjuvants Market Average Price (USD/Kg) by Region (2019-2024)
Table 53. Global Vaccine Adjuvants Market Average Price (USD/Kg) by Region (2025-2030)
Table 54. Global Vaccine Adjuvants Sales by Country: 2019 VS 2023 VS 2030 (MT)
Table 55. Global Vaccine Adjuvants Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 56. Global Vaccine Adjuvants Sales by Country (2019-2024) & (MT)
Table 57. Global Vaccine Adjuvants Sales Market Share by Country (2019-2024)
Table 58. Global Vaccine Adjuvants Sales by Country (2025-2030) & (MT)
Table 59. Global Vaccine Adjuvants Sales Market Share by Country (2025-2030)
Table 60. Global Vaccine Adjuvants Sales Value by Country (2019-2024) & (US$ Million)
Table 61. Global Vaccine Adjuvants Sales Value Market Share by Country (2019-2024)
Table 62. Global Vaccine Adjuvants Sales Value by Country (2025-2030) & (US$ Million)
Table 63. Global Vaccine Adjuvants Sales Value Market Share by Country (2025-2030)
Table 64. GSK Company Information
Table 65. GSK Business Overview
Table 66. GSK Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 67. GSK Vaccine Adjuvants Product Portfolio
Table 68. GSK Recent Development
Table 69. CSL Limited Company Information
Table 70. CSL Limited Business Overview
Table 71. CSL Limited Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 72. CSL Limited Vaccine Adjuvants Product Portfolio
Table 73. CSL Limited Recent Development
Table 74. Croda Company Information
Table 75. Croda Business Overview
Table 76. Croda Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 77. Croda Vaccine Adjuvants Product Portfolio
Table 78. Croda Recent Development
Table 79. SEPPIC Company Information
Table 80. SEPPIC Business Overview
Table 81. SEPPIC Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 82. SEPPIC Vaccine Adjuvants Product Portfolio
Table 83. SEPPIC Recent Development
Table 84. Novavax Company Information
Table 85. Novavax Business Overview
Table 86. Novavax Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 87. Novavax Vaccine Adjuvants Product Portfolio
Table 88. Novavax Recent Development
Table 89. SPI Pharma Company Information
Table 90. SPI Pharma Business Overview
Table 91. SPI Pharma Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 92. SPI Pharma Vaccine Adjuvants Product Portfolio
Table 93. SPI Pharma Recent Development
Table 94. Phibro Company Information
Table 95. Phibro Business Overview
Table 96. Phibro Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 97. Phibro Vaccine Adjuvants Product Portfolio
Table 98. Phibro Recent Development
Table 99. SDA BIO Company Information
Table 100. SDA BIO Business Overview
Table 101. SDA BIO Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 102. SDA BIO Vaccine Adjuvants Product Portfolio
Table 103. SDA BIO Recent Development
Table 104. Invivogen Company Information
Table 105. Invivogen Business Overview
Table 106. Invivogen Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 107. Invivogen Vaccine Adjuvants Product Portfolio
Table 108. Invivogen Recent Development
Table 109. Tj Kaiwei Company Information
Table 110. Tj Kaiwei Business Overview
Table 111. Tj Kaiwei Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 112. Tj Kaiwei Vaccine Adjuvants Product Portfolio
Table 113. Tj Kaiwei Recent Development
Table 114. OZ Biosciences Company Information
Table 115. OZ Biosciences Business Overview
Table 116. OZ Biosciences Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 117. OZ Biosciences Vaccine Adjuvants Product Portfolio
Table 118. OZ Biosciences Recent Development
Table 119. Brenntag Biosector Company Information
Table 120. Brenntag Biosector Business Overview
Table 121. Brenntag Biosector Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 122. Brenntag Biosector Vaccine Adjuvants Product Portfolio
Table 123. Brenntag Biosector Recent Development
Table 124. MVP Laboratories Company Information
Table 125. MVP Laboratories Business Overview
Table 126. MVP Laboratories Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 127. MVP Laboratories Vaccine Adjuvants Product Portfolio
Table 128. MVP Laboratories Recent Development
Table 129. Zhuoyue Company Information
Table 130. Zhuoyue Business Overview
Table 131. Zhuoyue Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 132. Zhuoyue Vaccine Adjuvants Product Portfolio
Table 133. Zhuoyue Recent Development
Table 134. Aphios Company Information
Table 135. Aphios Business Overview
Table 136. Aphios Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 137. Aphios Vaccine Adjuvants Product Portfolio
Table 138. Aphios Recent Development
Table 139. Key Raw Materials
Table 140. Raw Materials Key Suppliers
Table 141. Vaccine Adjuvants Distributors List
Table 142. Vaccine Adjuvants Customers List
Table 143. Research Programs/Design for This Report
Table 144. Authors List of This Report
Table 145. Secondary Sources
Table 146. Primary Sources
Table 1. Vaccine Adjuvants Industry Trends
Table 2. Vaccine Adjuvants Industry Drivers
Table 3. Vaccine Adjuvants Industry Opportunities and Challenges
Table 4. Vaccine Adjuvants Industry Restraints
Table 5. Global Vaccine Adjuvants Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global Vaccine Adjuvants Revenue Share by Company (2019-2024)
Table 7. Global Vaccine Adjuvants Sales Volume by Company (MT) & (2019-2024)
Table 8. Global Vaccine Adjuvants Sales Volume Share by Company (2019-2024)
Table 9. Global Vaccine Adjuvants Average Price (USD/Kg) of Company (2019-2024)
Table 10. Global Vaccine Adjuvants Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 11. Global Vaccine Adjuvants Key Company Manufacturing Base & Headquarters
Table 12. Global Vaccine Adjuvants Company, Product Type & Application
Table 13. Global Vaccine Adjuvants Company Commercialization Time
Table 14. Global Company Market Concentration Ratio (CR5 and HHI)
Table 15. Global Vaccine Adjuvants by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 16. Mergers & Acquisitions, Expansion
Table 17. Major Companies of Aluminum Adjuvant
Table 18. Major Companies of Emulsions Adjuvant
Table 19. Major Companies of Others
Table 20. Global Vaccine Adjuvants Sales Volume by Type 2019 VS 2023 VS 2030 (MT)
Table 21. Global Vaccine Adjuvants Sales Volume by Type (2019-2024) & (MT)
Table 22. Global Vaccine Adjuvants Sales Volume by Type (2025-2030) & (MT)
Table 23. Global Vaccine Adjuvants Sales Volume Share by Type (2019-2024)
Table 24. Global Vaccine Adjuvants Sales Volume Share by Type (2025-2030)
Table 25. Global Vaccine Adjuvants Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 26. Global Vaccine Adjuvants Sales Value by Type (2019-2024) & (US$ Million)
Table 27. Global Vaccine Adjuvants Sales Value by Type (2025-2030) & (US$ Million)
Table 28. Global Vaccine Adjuvants Sales Value Share by Type (2019-2024)
Table 29. Global Vaccine Adjuvants Sales Value Share by Type (2025-2030)
Table 30. Major Companies of Human Vaccine
Table 31. Major Companies of Veterinary Vaccine
Table 32. Global Vaccine Adjuvants Sales Volume by Application 2019 VS 2023 VS 2030 (MT)
Table 33. Global Vaccine Adjuvants Sales Volume by Application (2019-2024) & (MT)
Table 34. Global Vaccine Adjuvants Sales Volume by Application (2025-2030) & (MT)
Table 35. Global Vaccine Adjuvants Sales Volume Share by Application (2019-2024)
Table 36. Global Vaccine Adjuvants Sales Volume Share by Application (2025-2030)
Table 37. Global Vaccine Adjuvants Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 38. Global Vaccine Adjuvants Sales Value by Application (2019-2024) & (US$ Million)
Table 39. Global Vaccine Adjuvants Sales Value by Application (2025-2030) & (US$ Million)
Table 40. Global Vaccine Adjuvants Sales Value Share by Application (2019-2024)
Table 41. Global Vaccine Adjuvants Sales Value Share by Application (2025-2030)
Table 42. Global Vaccine Adjuvants Sales by Region: 2019 VS 2023 VS 2030 (MT)
Table 43. Global Vaccine Adjuvants Sales by Region (2019-2024) & (MT)
Table 44. Global Vaccine Adjuvants Sales Market Share by Region (2019-2024)
Table 45. Global Vaccine Adjuvants Sales by Region (2025-2030) & (MT)
Table 46. Global Vaccine Adjuvants Sales Market Share by Region (2025-2030)
Table 47. Global Vaccine Adjuvants Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 48. Global Vaccine Adjuvants Sales Value by Region (2019-2024) & (US$ Million)
Table 49. Global Vaccine Adjuvants Sales Value Share by Region (2019-2024)
Table 50. Global Vaccine Adjuvants Sales Value by Region (2025-2030) & (US$ Million)
Table 51. Global Vaccine Adjuvants Sales Value Share by Region (2025-2030)
Table 52. Global Vaccine Adjuvants Market Average Price (USD/Kg) by Region (2019-2024)
Table 53. Global Vaccine Adjuvants Market Average Price (USD/Kg) by Region (2025-2030)
Table 54. Global Vaccine Adjuvants Sales by Country: 2019 VS 2023 VS 2030 (MT)
Table 55. Global Vaccine Adjuvants Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 56. Global Vaccine Adjuvants Sales by Country (2019-2024) & (MT)
Table 57. Global Vaccine Adjuvants Sales Market Share by Country (2019-2024)
Table 58. Global Vaccine Adjuvants Sales by Country (2025-2030) & (MT)
Table 59. Global Vaccine Adjuvants Sales Market Share by Country (2025-2030)
Table 60. Global Vaccine Adjuvants Sales Value by Country (2019-2024) & (US$ Million)
Table 61. Global Vaccine Adjuvants Sales Value Market Share by Country (2019-2024)
Table 62. Global Vaccine Adjuvants Sales Value by Country (2025-2030) & (US$ Million)
Table 63. Global Vaccine Adjuvants Sales Value Market Share by Country (2025-2030)
Table 64. GSK Company Information
Table 65. GSK Business Overview
Table 66. GSK Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 67. GSK Vaccine Adjuvants Product Portfolio
Table 68. GSK Recent Development
Table 69. CSL Limited Company Information
Table 70. CSL Limited Business Overview
Table 71. CSL Limited Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 72. CSL Limited Vaccine Adjuvants Product Portfolio
Table 73. CSL Limited Recent Development
Table 74. Croda Company Information
Table 75. Croda Business Overview
Table 76. Croda Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 77. Croda Vaccine Adjuvants Product Portfolio
Table 78. Croda Recent Development
Table 79. SEPPIC Company Information
Table 80. SEPPIC Business Overview
Table 81. SEPPIC Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 82. SEPPIC Vaccine Adjuvants Product Portfolio
Table 83. SEPPIC Recent Development
Table 84. Novavax Company Information
Table 85. Novavax Business Overview
Table 86. Novavax Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 87. Novavax Vaccine Adjuvants Product Portfolio
Table 88. Novavax Recent Development
Table 89. SPI Pharma Company Information
Table 90. SPI Pharma Business Overview
Table 91. SPI Pharma Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 92. SPI Pharma Vaccine Adjuvants Product Portfolio
Table 93. SPI Pharma Recent Development
Table 94. Phibro Company Information
Table 95. Phibro Business Overview
Table 96. Phibro Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 97. Phibro Vaccine Adjuvants Product Portfolio
Table 98. Phibro Recent Development
Table 99. SDA BIO Company Information
Table 100. SDA BIO Business Overview
Table 101. SDA BIO Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 102. SDA BIO Vaccine Adjuvants Product Portfolio
Table 103. SDA BIO Recent Development
Table 104. Invivogen Company Information
Table 105. Invivogen Business Overview
Table 106. Invivogen Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 107. Invivogen Vaccine Adjuvants Product Portfolio
Table 108. Invivogen Recent Development
Table 109. Tj Kaiwei Company Information
Table 110. Tj Kaiwei Business Overview
Table 111. Tj Kaiwei Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 112. Tj Kaiwei Vaccine Adjuvants Product Portfolio
Table 113. Tj Kaiwei Recent Development
Table 114. OZ Biosciences Company Information
Table 115. OZ Biosciences Business Overview
Table 116. OZ Biosciences Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 117. OZ Biosciences Vaccine Adjuvants Product Portfolio
Table 118. OZ Biosciences Recent Development
Table 119. Brenntag Biosector Company Information
Table 120. Brenntag Biosector Business Overview
Table 121. Brenntag Biosector Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 122. Brenntag Biosector Vaccine Adjuvants Product Portfolio
Table 123. Brenntag Biosector Recent Development
Table 124. MVP Laboratories Company Information
Table 125. MVP Laboratories Business Overview
Table 126. MVP Laboratories Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 127. MVP Laboratories Vaccine Adjuvants Product Portfolio
Table 128. MVP Laboratories Recent Development
Table 129. Zhuoyue Company Information
Table 130. Zhuoyue Business Overview
Table 131. Zhuoyue Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 132. Zhuoyue Vaccine Adjuvants Product Portfolio
Table 133. Zhuoyue Recent Development
Table 134. Aphios Company Information
Table 135. Aphios Business Overview
Table 136. Aphios Vaccine Adjuvants Sales (MT), Value (US$ Million), Price (USD/Kg) and Gross Margin (2019-2024)
Table 137. Aphios Vaccine Adjuvants Product Portfolio
Table 138. Aphios Recent Development
Table 139. Key Raw Materials
Table 140. Raw Materials Key Suppliers
Table 141. Vaccine Adjuvants Distributors List
Table 142. Vaccine Adjuvants Customers List
Table 143. Research Programs/Design for This Report
Table 144. Authors List of This Report
Table 145. Secondary Sources
Table 146. Primary Sources
LIST OF FIGURES
Figure 1. Vaccine Adjuvants Product Picture
Figure 2. Global Vaccine Adjuvants Sales Value (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Vaccine Adjuvants Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Vaccine Adjuvants Sales (2019-2030) & (MT)
Figure 5. Global Vaccine Adjuvants Sales Average Price (USD/Kg) & (2019-2030)
Figure 6. Global Vaccine Adjuvants Company Revenue Ranking in 2023 (US$ Million)
Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 9. Aluminum Adjuvant Picture
Figure 10. Emulsions Adjuvant Picture
Figure 11. Others Picture
Figure 12. Global Vaccine Adjuvants Sales Volume by Type (2019 VS 2023 VS 2030) & (MT)
Figure 13. Global Vaccine Adjuvants Sales Volume Share 2019 VS 2023 VS 2030
Figure 14. Global Vaccine Adjuvants Sales Volume Share by Type (2019-2030)
Figure 15. Global Vaccine Adjuvants Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Vaccine Adjuvants Sales Value Share 2019 VS 2023 VS 2030
Figure 17. Global Vaccine Adjuvants Sales Value Share by Type (2019-2030)
Figure 18. Human Vaccine Picture
Figure 19. Veterinary Vaccine Picture
Figure 20. Global Vaccine Adjuvants Sales Volume by Application (2019 VS 2023 VS 2030) & (MT)
Figure 21. Global Vaccine Adjuvants Sales Volume Share 2019 VS 2023 VS 2030
Figure 22. Global Vaccine Adjuvants Sales Volume Share by Application (2019-2030)
Figure 23. Global Vaccine Adjuvants Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 24. Global Vaccine Adjuvants Sales Value Share 2019 VS 2023 VS 2030
Figure 25. Global Vaccine Adjuvants Sales Value Share by Application (2019-2030)
Figure 26. Global Vaccine Adjuvants Sales by Region: 2019 VS 2023 VS 2030 (MT)
Figure 27. Global Vaccine Adjuvants Sales Market Share by Region: 2019 VS 2023 VS 2030
Figure 28. Global Vaccine Adjuvants Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 29. Global Vaccine Adjuvants Sales Value Share by Region: 2019 VS 2023 VS 2030
Figure 30. North America Vaccine Adjuvants Sales Value (2019-2030) & (US$ Million)
Figure 31. North America Vaccine Adjuvants Sales Value Share by Country (%), 2023 VS 2030
Figure 32. Europe Vaccine Adjuvants Sales Value (2019-2030) & (US$ Million)
Figure 33. Europe Vaccine Adjuvants Sales Value Share by Country (%), 2023 VS 2030
Figure 34. Asia-Pacific Vaccine Adjuvants Sales Value (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Vaccine Adjuvants Sales Value Share by Country (%), 2023 VS 2030
Figure 36. Latin America Vaccine Adjuvants Sales Value (2019-2030) & (US$ Million)
Figure 37. Latin America Vaccine Adjuvants Sales Value Share by Country (%), 2023 VS 2030
Figure 38. Middle East & Africa Vaccine Adjuvants Sales Value (2019-2030) & (US$ Million)
Figure 39. Middle East & Africa Vaccine Adjuvants Sales Value Share by Country (%), 2023 VS 2030
Figure 40. USA Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 41. USA Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 42. USA Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 43. Canada Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 44. Canada Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 45. Canada Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 46. Germany Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 47. Germany Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 48. Germany Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 49. France Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 50. France Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 51. France Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 52. U.K. Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 53. U.K. Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 54. U.K. Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 55. Italy Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 56. Italy Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 57. Italy Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 58. Netherlands Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 59. Netherlands Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 60. Netherlands Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 61. Nordic Countries Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 62. Nordic Countries Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 63. Nordic Countries Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 64. China Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 65. China Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 66. China Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 67. Japan Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 68. Japan Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 69. Japan Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 70. South Korea Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 71. South Korea Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 72. South Korea Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 73. Southeast Asia Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 74. Southeast Asia Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 75. Southeast Asia Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 76. India Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 77. India Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 78. India Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 79. Australia Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 80. Australia Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 81. Australia Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 82. Mexico Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 83. Mexico Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 84. Mexico Vaccine Adjuvants Sales Value Share by Application, 20
Figure 1. Vaccine Adjuvants Product Picture
Figure 2. Global Vaccine Adjuvants Sales Value (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Vaccine Adjuvants Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Vaccine Adjuvants Sales (2019-2030) & (MT)
Figure 5. Global Vaccine Adjuvants Sales Average Price (USD/Kg) & (2019-2030)
Figure 6. Global Vaccine Adjuvants Company Revenue Ranking in 2023 (US$ Million)
Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 9. Aluminum Adjuvant Picture
Figure 10. Emulsions Adjuvant Picture
Figure 11. Others Picture
Figure 12. Global Vaccine Adjuvants Sales Volume by Type (2019 VS 2023 VS 2030) & (MT)
Figure 13. Global Vaccine Adjuvants Sales Volume Share 2019 VS 2023 VS 2030
Figure 14. Global Vaccine Adjuvants Sales Volume Share by Type (2019-2030)
Figure 15. Global Vaccine Adjuvants Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Vaccine Adjuvants Sales Value Share 2019 VS 2023 VS 2030
Figure 17. Global Vaccine Adjuvants Sales Value Share by Type (2019-2030)
Figure 18. Human Vaccine Picture
Figure 19. Veterinary Vaccine Picture
Figure 20. Global Vaccine Adjuvants Sales Volume by Application (2019 VS 2023 VS 2030) & (MT)
Figure 21. Global Vaccine Adjuvants Sales Volume Share 2019 VS 2023 VS 2030
Figure 22. Global Vaccine Adjuvants Sales Volume Share by Application (2019-2030)
Figure 23. Global Vaccine Adjuvants Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 24. Global Vaccine Adjuvants Sales Value Share 2019 VS 2023 VS 2030
Figure 25. Global Vaccine Adjuvants Sales Value Share by Application (2019-2030)
Figure 26. Global Vaccine Adjuvants Sales by Region: 2019 VS 2023 VS 2030 (MT)
Figure 27. Global Vaccine Adjuvants Sales Market Share by Region: 2019 VS 2023 VS 2030
Figure 28. Global Vaccine Adjuvants Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 29. Global Vaccine Adjuvants Sales Value Share by Region: 2019 VS 2023 VS 2030
Figure 30. North America Vaccine Adjuvants Sales Value (2019-2030) & (US$ Million)
Figure 31. North America Vaccine Adjuvants Sales Value Share by Country (%), 2023 VS 2030
Figure 32. Europe Vaccine Adjuvants Sales Value (2019-2030) & (US$ Million)
Figure 33. Europe Vaccine Adjuvants Sales Value Share by Country (%), 2023 VS 2030
Figure 34. Asia-Pacific Vaccine Adjuvants Sales Value (2019-2030) & (US$ Million)
Figure 35. Asia-Pacific Vaccine Adjuvants Sales Value Share by Country (%), 2023 VS 2030
Figure 36. Latin America Vaccine Adjuvants Sales Value (2019-2030) & (US$ Million)
Figure 37. Latin America Vaccine Adjuvants Sales Value Share by Country (%), 2023 VS 2030
Figure 38. Middle East & Africa Vaccine Adjuvants Sales Value (2019-2030) & (US$ Million)
Figure 39. Middle East & Africa Vaccine Adjuvants Sales Value Share by Country (%), 2023 VS 2030
Figure 40. USA Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 41. USA Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 42. USA Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 43. Canada Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 44. Canada Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 45. Canada Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 46. Germany Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 47. Germany Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 48. Germany Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 49. France Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 50. France Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 51. France Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 52. U.K. Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 53. U.K. Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 54. U.K. Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 55. Italy Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 56. Italy Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 57. Italy Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 58. Netherlands Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 59. Netherlands Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 60. Netherlands Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 61. Nordic Countries Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 62. Nordic Countries Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 63. Nordic Countries Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 64. China Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 65. China Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 66. China Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 67. Japan Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 68. Japan Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 69. Japan Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 70. South Korea Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 71. South Korea Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 72. South Korea Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 73. Southeast Asia Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 74. Southeast Asia Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 75. Southeast Asia Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 76. India Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 77. India Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 78. India Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 79. Australia Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 80. Australia Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 81. Australia Vaccine Adjuvants Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 82. Mexico Vaccine Adjuvants Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 83. Mexico Vaccine Adjuvants Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 84. Mexico Vaccine Adjuvants Sales Value Share by Application, 20
